83.9 F
San Fernando
Friday, Jan 27, 2023
-Advertisement-
Array

FDA Panel Likes Kythera Chin Fat Drug

A Food and Drug Administration panel on Monday recommended approval of Kythera Biopharmaceuticals Inc.’s novel treatment for chin fat. The injectable chemical, ATX-101, dissolves fat and would be the Westlake Village company’s first commercial product. The FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted 17-0 in favor of its sale. While the recommendation by the panel of outside experts isn’t binding, the agency usually follows such recommendations. If ATX-101 is approved by the FDA, Kythera plans to launch it during the second half this year. “This milestone demonstrates our commitment to developing first-in-class aesthetic products through a focus on scientific rigor and innovation,” Chief Executive Keith Leonard said in a statement. Last week, in a separate opinion, FDA staff recommended approval of the drug, sending the stock up nearly 22 percent. Shares closed down $1.96, or 3.7 percent, to $51.17 on the Nasdaq.

Joel Russel
Joel Russel
Joel Russell joined the Los Angeles Business Journal in 2006 as a reporter. He transferred to sister publication San Fernando Valley Business Journal in 2012 as managing editor. Since he assumed the position of editor in 2015, the Business Journal has been recognized four times as the best small-circulation tabloid business publication in the country by the Alliance of Area Business Publishers. Previously, he worked as senior editor at Hispanic Business magazine and editor of Business Mexico.
-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-